Migraine Market information, by types (Episodic and Chronic), by
treatment type (Preventive and Abortive), by drug class (Triptans, Ergots, and
Others) - Global Forecast to 2022
Market Analysis
The global Migraine Market is anticipated to grow at an
impressive CAGR between 2013-2022, states the latest Market Research Future
(MRFR) report. Migraine is basically a neurological condition which can result
in multiple symptoms. It is characterized by a debilitating, intense headache.
Often migraine runs in families and can affect every age group. Sensitivity to
sound and light, difficulty speaking, tingling or numbness, vomiting, and
nausea are common symptoms of migraines.
Migraine may begin during
childhood, or it may not occur until early adulthood. Generally, women are more
likely to suffer from migraines than men. Migraine with aura or classic
migraines and without aura or common migraine are the two common categories of
migraine. The pain mostly affects the area of the forehead, is usually on one
side of the head, yet may shift, or occur on both sides of the head.
Numerous factors are pushing the
growth of the market such as growing awareness regarding the prevention and
also treatment of migraine, rising healthcare expenditure, launch and FDA
approval of new migraine drugs, rising cigarette consumption, increasing intake
of hormonal medications, lifestyle changes, rising disease prevalence, and
stressed lifestyle. Additional factors propelling the growth of the migraine
market include accelerating economic growth, rising prevalence of migraine,
increasing female population, demand for hormonal medications, high unmet
needs, and launch of calcitonin gene-related peptide (CGRP).
On the contrary, different side
effects from migraine drugs, stringent government regulations, regulatory
challenges, scarcity of proper diagnosis, rising preference of alternative
therapies, and increasing investment in drug R&D are factors that may
restrict the migraine market growth during the forecast period.
Market Segmentation
The global migraine market has
been segmented in terms of drug class, types, and treatment types.
By types, the migraine market is
segmented into chronic as well as episodic. Of these, the episodic segment will
lead the market during the forecast period owing to its increasing
prevalence.
By treatment types, the migraine
market is segmented into abortive and preventive. Of these, the abortive
segment will dominate the market during the forecast period for the ease of
self-administration in those with migraines accompanied by vomiting and
nausea.
By drug class, the migraine
market is segmented into ergots, triptans, and others. Of these, triptans will
have maximum share in the market during the forecast period.
Regional Analysis
The global migraine market
report is geographically distributed across the following key regions: North
America, Europe, the Asia Pacific (APAC), and the Rest of the World (RoW).
Among these, North America will have the lion’s share in the market during the
forecast period. Various factors propelling the growth of the migraine market
in the region include the launch of CGRP based therapies, adoption of novel
therapeutics, huge target population, especially in the US, increasing R&D
activities in the region, and increasing incidence of migraine. The US is the
major contributor in the region.
The migraine market in the APAC
region will have favorable growth during the forecast period. Various factors
propelling the growth of the migraine market in the region include increasing
healthcare expenditure, growing disease awareness, huge underserved population,
and low-cost production of drugs.
The migraine market in Europe
will have a notable growth during the forecast period for rising stress levels,
changing lifestyles, and rising incidence of hormonal imbalance.
The migraine market in the RoW
will have stable growth during the forecast period.
Key Players
Notable players profiled in the global migraine market report include
Pfizer, Inc., Eisai Inc., Impax Laboratories, Eli Lilly and Company, Abbott
Laboratories, Allegan, Luitpold Pharmaceuticals, Klaria, Johnson and Johnson,
Kowa Pharmaceuticals America, GlaxoSmithKline plc., OptiNose, Meda, AstraZeneca
plc, Merck, and others. Key players have used specific strategies to stay head
and shoulders above others in the competition, such as collaborations,
expansions, mergers and acquisitions, research and development activities, new
product launches, and more.
Industry News
October 2019: Eli Lilly’s Reyvow
has received FDA approval to treat acute migraines. It is the only and foremost
medicine that has received approval from the FDA to treat acute migraines.
No comments:
Post a Comment